First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 ENV (IPCAVD 002)

Journal of Infectious Diseases

Volumn 210, Issue 7, 2014, Pages 1052-1061

  Baden, Lindsey R ^a,b,c   Walsh, Stephen R ^a,b,c   Seaman, Michael S ^b,c   Johnson, Jennifer A ^a,c   Tucker, Robert P ^a   Kleinjan, Jane A ^a   Gothing, Jon A ^a   Engelson, Brian A ^a   Carey, Brittany R ^b   Oza, Avinash ^b   Bajimaya, Shringkhala ^b   Peter, Lauren ^b   Bleckwehl, Chelsea ^b   Abbink, Peter ^b   Pau, Maria G ^f   Weijtens, Mo ^f   Kunchai, Meghan ^d   Swann, Edith M ^e   Wolff, Mark ^d   Dolin, Raphael ^b,c   Barouch, Dan H ^b,c   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d EMMES CORPORATION   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Adenovirus 5 HVR48; Dose escalation; HIV vaccine; Immunogenicity; Safety

Indexed keywords

HEXON CHIMERIC ADENOVIRUS VECTOR EXPRESSING HIV 1 ENV; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IPCAVD 002; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; CAPSID PROTEIN; DRUG CARRIER; HEXON CAPSID PROTEIN, ADENOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MALAISE; MALE; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; VIRUS PARTICLE; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADENOVIRUSES, HUMAN; ADOLESCENT; ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CAPSID PROTEINS; DOUBLE-BLIND METHOD; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HIV ANTIBODIES; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLACEBOS; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84922393212     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu217     Document Type: Article

References (38)

1. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93.
2. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-65.
3. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894-905.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.
5. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011;11:507-15.
6. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-71.
7. Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013;369:2083-92.
8. Johnson JA, Barouch DH, Baden LR. Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS 2013;8:411-9.
9. Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011;29:5203-9.
10. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010;28:950-7.
11. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010;5:386-90.
12. Michael NL. Rare serotype adenoviral vectors for HIV vaccine development. J Clin Invest 2012;122:25-7.
13. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482:89-93.
14. Li H, Rhee EG, Masek-Hammerman K, Teigler JE, Abbink P, Barouch DH. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 2012;86:10862-5.
15. Liu J, Ewald BA, Lynch DM, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008;82:4844-52.
16. Lore K, Adams WC, Havenga MJ, et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 2007;179:1721-9.
17. Baden LR, Walsh SR, Seaman MS, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 2013;207:240-7.
18. Keefer MC, Gilmour J, Hayes P, et al. A phase I double blind, placebocontrolled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 2012;7:e41936.
19. Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011;85:4222-33.
20. Radosevic K, Rodriguez A, Lemckert AA, et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 2010;17:1687-94.
21. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005;174:7179-85.
22. Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006;441:239-43.
23. Barouch DH, Liu J, Lynch DM, et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2009;83:9584-90.
24. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006;194:1638-49.
25. Kong WP, Huang Y, Yang ZY, Chakrabarti BK, Moodie Z, Nabel GJ. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 2003;77:12764-72.
26. Andrasik MP, Karuna ST, Nebergall M, Koblin BA, Kublin JG. Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives. Vaccine 2013;31:4398-405.
27. Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci USA 2012;109:8694-8.
28. Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol 2012;86:9590-8.
29. Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 2012;86:625-9.
30. Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 2012;86:1267-72.
31. Morse MA, Chaudhry A, Gabitzsch ES, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 2013;62:1293-301.
32. Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirusbased tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013;5:205ra134.
33. Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010;5:e12873.
34. Coughlan L, Bradshaw AC, Parker AL, et al. Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther 2012;20:2268-81.
35. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-86.
36. Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011;3:81ra36.
37. Barouch DH, Stephenson KE, Borducchi EN, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013;155:531-9.
38. Roederer M, Keele BF, Schmidt SD, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014;505:502-8.